Navigation Links
More Precise Prostate Cancer Screening on Horizon
Date:9/2/2011

NEW YORK, Sept. 2, 2011 /PRNewswire/ -- This September, during Prostate Cancer Awareness Month, there is talk of a new prostate cancer screening method that may change the face of prostate cancer diagnoses. Initial data gathered by two Cleveland hospitals and one Boston hospital, analyzed by the National Cancer Institute, indicates significantly more accurate results with a new urine screening. Dr. David Samadi, Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center, is encouraged by the potential of this new screening to more accurately identify prostate cancer in men. "Increasing awareness of prostate cancer and the importance of early screening is key," said Dr. Samadi, "but being able to share potential advancements in our screening capabilities, especially during Prostate Cancer Awareness Month, is even better."

(Photo:  http://photos.prnewswire.com/prnh/20110902/NY61902 )

This new PSA/SIA assay is believed to be more accurate because it is able to evaluate a wide range of ultra-structural changes in the PSA (Prostate-Specific Antigen) protein, rather than just identifying a patient's PSA level, as the current test does. "This test appears to have a way of deciphering the PSA molecular structures of cancerous cells vs. those of non-cancerous cell," explains Dr. Samadi. "While the PSA test is critical to identifying prostate cancer in men, there are some limitations of the current screening. We see more false positive and false negatives than are ideal." The current PSA blood test is believed to result in false negatives 15 percent of the time and false positives 55-75% of the time. "Unfortunately, a false positive can be very traumatizing to a patient. If we could hone the findings to more accurate positives, the need for prostate biopsies would likely decline. And, of course, a false negative has significant implications," said Dr. Samadi, who believes the current PSA test to be indispensable, despite its limitations.

On the basis that blood PSA level alone is not a clear enough indicator of the presence of prostate cancer, this study focused on the evaluation of microscopic structural changes in urine. As an assay, it is believed that this more sensitive test may be able to determine not only the presence of prostate cancer, but its level or aggressiveness, too. "Improvements to prostate cancer staging would be extremely valuable, as well," Dr. Samadi added. "Too often, prostate cancer patients believe they have plenty of time. In reality, prostate cancer can progress very quickly, without notice. Robotic prostatectomy surgery erases the unknown; more accurate staging could help patients reach the decision for life-saving radical prostatectomy surgery sooner."

Researchers conducted the urine-based test on 222 men across three hospitals. The results showed a 100 percent sensitivity, meaning no false negatives; an 80 percent specificity was found, a drastic reduction in false positives from the current PSA test. Further clinical research will be conducted and the test should be available within a year. The test is made by AnalizaDX, Inc., a Cleveland-based biotech company, who will initially conduct the testing of submitted samples at their facilities. "I do hope continued research shows the same level of success with the PSA/SIA assay. Early prostate cancer tests are our best defense," said Dr. Samadi, "I look forward to our ability to deliver increased screening accuracy to our patients."

More can be seen from prostate cancer expert, Dr. David Samadi, who is also part of the Fox News Medical A-Team.

New Study On Prostate Cancer Screening Effectiveness
http://www.youtube.com/watch?v=KFH1XFgoziQ

Comparing Prostate Cancer Treatment Options - Robotic Surgery Vs. Watchful Waiting
http://www.youtube.com/watch?v=9dC4T9JAJss

Related Links: Smart-Surgery.com


'/>"/>
SOURCE RoboticOncology.com
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Life Technologies Signs Exclusive License Agreement for TAL Effector Technology That Enables Synthetic Biologists to Precisely Control Gene Expression in Engineered Organisms
2. Hydrogels used to make precise new sensor
3. The perfect nanocube: Precise control of size, shape and composition
4. NISTs second quantum logic clock based on aluminum ion is now worlds most precise clock
5. Research: Dosage of Morphine for ill Newborns Still too Imprecise
6. SmartGenes Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital
7. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
8. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
9. Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology
10. Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment
11. New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems is ... log work hours, for employers to make sure the right employees are actually signing ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
Breaking Biology News(10 mins):